In addition, apelin stimulation increases miR-106a-5p expression, while treatment of prostate cancer cells with the miR-106a-5p inhibitor reversed apelin-induced inhibition of TIMP2 synthesis and promotion of cell migration and invasion. The gene discussed is APLN; the disease is prostate cancer.